TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Dec 31, 2023. Filed Feb 12, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 12, 2024

TEVA$42.97+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of cash flows

	Year ended December 31,
	2023	2022	2021
Operating activities:
Net income (loss)	$(615)	$(2,499)	$456
Adjustments to reconcile net income (loss) to net cash provided by operations:
Impairment of goodwill, long-lived assets and assets held for sale	1,078	2,447	584
Depreciation and amortization	1,153	1,308	1,330
Net change in operating assets and liabilities	(72)	1,355	(1,701)
Deferred income taxes — net and uncertain tax positions	(317)	(1,064)	(120)
Stock-based compensation	121	124	119
Research and development in process	—	—	10
Net loss (gain) from investments and from sale of business and long-lived assets	(41)	10	104
Other items	61	(91)	16
Net cash provided by (used in) operating activities	1,368	1,590	798
Investing activities:
Beneficial interest collected in exchange for securitized trade receivables	1,477	1,140	1,648
Purchases of property, plant and equipment and intangible assets	(526)	(548)	(562)
Proceeds from sale of business and long-lived assets	68	68	311
Purchases of investments and other assets	(46)	(1)	(47)
Proceeds from sale of investments	—	4	172
Acquisitions of businesses, net of cash acquired	—	(7)	—
Other investing activities	(5)	—	1
Net cash provided by (used in) investing activities	968	656	1,523
Financing activities:
Repayment of senior notes and loans and other long term liabilities	(4,152)	(1,369)	(6,649)
Proceeds from senior notes, net of issuance costs	2,451	—	4,974
Proceeds from short term debt	700	—	700
Repayment of short term debt	(700)	—	(700)
Redemption of convertible debentures	—	—	(491)
Other financing activities	(212)	(118)	(6)
Net cash provided by (used in) financing activities	(1,913)	(1,487)	(2,172)
Translation adjustment on cash and cash equivalents	(30)	(123)	(128)
Net change in cash, cash equivalents and restricted cash	393	636	21
Balance of cash, cash equivalents and restricted cash at beginning of year	2,834	2,198	2,177
Balance of cash, cash equivalents and restricted cash at end of year	$3,227	$2,834	$2,198
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
Cash and cash equivalents	3,226	2,801	2,165
Restricted cash included in other current assets	1	33	33
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	3,227	2,834	2,198

Supplemental cash flow information:

	Year ended December 31,
	2023	2022	2021
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized trade receivables	$1,446	$1,189	$1,635
Dividend declared to non-controlling interests	67	$—	$—
Cash paid during the year for:
Interest	$1,078	$948	$913
Income taxes, net of refunds	$298	$543	$495

Net change in operating assets and liabilities:

	Year ended December 31,
	2023	2022	2021
Other current assets	$(1,525)	$(828)	$(2,271)
Trade payables, accrued expenses, employee-related obligations and other liabilities	1,588	2,012	764
Trade receivables net of sales reserves and allowances	12	334	(574)
Inventories	(147)	(163)	380
	$(72)	$1,355	$(1,701)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.